Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) received a drug registration certificate from Macau's drug regulator for its carbocysteine oral solution, according to a Shanghai bourse filing on Thursday.
The certificate covers 0.5 g / 10 mL dosage of the drug, which is used to treat phlegm caused by chronic bronchitis, bronchial asthma, and related diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.